Retail traders overwhelmingly picked Novo Nordisk as the strongest long-term obesity play in a 1,100-vote poll, citing its GLP-1 pipeline and sector-wide M&A momentum. Sentiment split sharply, bullish for Novo, bearish for Eli Lilly, Viking and Hims. The poll comes as competition intensifies despite Lilly hitting a $1 trillion valuation.